Compare ICFI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | VIR |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2006 | 2019 |
| Metric | ICFI | VIR |
|---|---|---|
| Price | $89.73 | $9.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $99.25 | $19.43 |
| AVG Volume (30 Days) | 207.7K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $1,229,162,000.00 | $68,556,000.00 |
| Revenue This Year | $4.12 | $270.22 |
| Revenue Next Year | $5.33 | N/A |
| P/E Ratio | $34.13 | ★ N/A |
| Revenue Growth | ★ 3.72 | N/A |
| 52 Week Low | $58.83 | $4.35 |
| 52 Week High | $101.50 | $11.66 |
| Indicator | ICFI | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 58.52 |
| Support Level | $84.28 | $9.51 |
| Resistance Level | $89.91 | $9.80 |
| Average True Range (ATR) | 3.34 | 0.42 |
| MACD | -0.31 | 0.10 |
| Stochastic Oscillator | 53.91 | 77.13 |
ICF International Inc provides professional services and technology-based solutions, including management, technology and policy consulting and implementation services, to government and commercial clients in the U.S. and internationally. Its government clients include U.S. federal agencies, state and local governments and international governments, as well as commercial clients inside and outside the U.S. It supports clients in Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs; and Security and Other Civilian and Commercial markets. The company delivers services across the life cycle of a policy, program or project through Advisory Services, Program Implementation, Analytics Services, Digital Services and Engagement Services.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.